Related Experiment Video
Updated: Sep 2, 2025
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
Published on: June 2, 2022
Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents
Sarah Huff1, Indrasena Reddy Kummetha1, Lingzhi Zhang1
1Division of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, California 92093, United States.
Abstract:
Aberrant regulation of N6-methyladenosine (m6A) RNA modification has been implicated in the progression of multiple diseases, including cancer. Previously, we identified a small molecule inhibitor of the m6A demethylase fat mass- and obesity-associated protein (FTO), which removes both m6A and N6,2'-O-dimethyladenosine (m6Am) RNA modifications. In this work, we describe the rational design and optimization of a new class of FTO inhibitors derived from our previous lead FTO-04 with nanomolar potency and high selectivity against the homologous m6A RNA demethylase ALKBH5. The oxetanyl class of compounds comprise competitive inhibitors of FTO with potent antiproliferative effects in glioblastoma, acute myeloid leukemia, and gastric cancer models where lead FTO-43 demonstrated potency comparable to clinical chemotherapeutic 5-fluorouracil. Furthermore, FTO-43 increased m6A and m6Am levels in a manner comparable to FTO knockdown in gastric cancer cells and regulated Wnt/PI3K-Akt signaling pathways. The oxetanyl class contains significantly improved anticancer agents with a variety of applications beyond glioblastoma.
Insights
New FTO inhibitors show potent anticancer effects. These compounds target aberrant N6-methyladenosine (m6A) RNA modification, demonstrating significant antiproliferative activity in models of glioblastoma, leukemia, and gastric cancer.
Area of Science:
- Molecular Biology
- Oncology
- Medicinal Chemistry
Background:
- Aberrant N6-methyladenosine (m6A) RNA modification is linked to cancer progression.
- Fat mass- and obesity-associated protein (FTO) is an m6A demethylase implicated in disease.
- Previous work identified FTO inhibitors, prompting further optimization.
Purpose of the Study:
- To design and optimize novel, potent, and selective FTO inhibitors.
- To evaluate the anticancer efficacy of the new inhibitor class.
- To investigate the mechanism of action of the lead compounds.
Main Methods:
- Rational drug design and medicinal chemistry optimization.
- Biochemical assays to determine FTO inhibition and selectivity.
- Antiproliferative assays in cancer cell lines and xenograft models.
- RNA modification analysis (m6A and m6Am levels) and Western blotting for signaling pathways.
Main Results:
- A new class of oxetanyl FTO inhibitors was developed with nanomolar potency.
- Lead compound FTO-43 exhibited high selectivity against ALKBH5 and potent antiproliferative effects in glioblastoma, AML, and gastric cancer models.
- FTO-43 demonstrated efficacy comparable to 5-fluorouracil and modulated m6A/m6Am levels and Wnt/PI3K-Akt signaling.
Conclusions:
- The oxetanyl class of FTO inhibitors represents promising anticancer agents.
- These compounds offer potential therapeutic applications beyond glioblastoma.
- Targeting FTO-mediated RNA demethylation is a viable strategy for cancer treatment.
Related Concept Videos
01:22MicroRNAs
02:15Experimental RNAi